glp-1 for addiction treatment Agonist GLP‑1 drugs may fight addiction

Melatonin has been reported to bind KEAP1, thereby disrupting this interaction and permitting NRF2 to translocate to the nucleus where it can activate antioxidant response element (ARE)-driven gene expression ( Gclc and Gclm ( Gclc and Gclm , supporting the conclusion that melatonin augments NRF2 transcriptional activity in ILC2s

1 The same applies to other commonly prescribed SSRIs, like citalopram, fluoxetine, and escitalopram, as well as SNRIs, like venlafaxine and duloxetine

CZ: Writing review & editing

Additionally, mRNA sequencing has inherent limitations and does not directly represent changes in protein levels or activity